Investing in Pharmaceutical Innovation and Better Outcomes for All Stakeholders
Camargo Capital invests in early-stage biopharma and biotech companies who share our vision to address unmet patient needs through breakthrough science. We partner with entrepreneurs from industry and academia, providing targeted capital and value-added strategic support to advance companies through critical growth stages. Our purpose is to help bring these therapies one step closer to the patients who need them.
Differentiated Capital Partner
Our differentiated strategy is rooted in hands-on collaboration. For nearly two decades, Camargo has helped clients navigate regulatory, development and commercial challenges for complex programs where no playbook exists. We bring multi-disciplinary drug development expertise, serving as an extension of the operating team to maximize value creation and preservation.
Camargo Capital typically supports companies raising initial institutional capital in Series A or B seed funding. Our investment and strategic support enable portfolio partners to establish proof-of-concept data and reach critical value-enhancing milestones.
Camargo Capital currently has 9 active investments in early-stage biopharma and biotech companies.
For more information, contact us.